增强PDAC治疗:Decitabine-olaparib协同作用的目标是依赖KRAS的瘤
Giorgia Anastasio1, Michela Felaco1,2, Alessia Lamolinara3,4
1Institute of Biochemistry and Cellular Biology, National Research Council, Monterotondo-Scalo, 00015 Rome, Italy.
iScience
|February 26, 2025
概括
低剂量德平 (DEC) 与olaparib (OLA) 结合显示在KRAS突变的胰腺癌中增强了抗瘤活性. 这种组合针对DNA损伤反应通路,为胰腺管道腺癌提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 胰腺管腺癌 (PDAC) 对化疗反应不佳,因此需要新的生物标志物来个性化治疗策略.
- 基尔斯顿大鼠肉瘤病毒瘤基因同源 (KRAS) 突变在PDAC中很普遍,并且依赖KRAS (dKRAS) 的瘤具有治疗脆弱性.
- 低甲基化剂decitabine (DEC) 在dKRAS-PDAC细胞中表现出敏感性,但在固体瘤中由于副作用而受到限制.
研究的目的:
- 在dKRAS-PDAC.中研究低剂量德氨酸 (DEC) 与多 (ADP-ribose) 聚合酶 (PARP) 抑制剂olaparib (OLA) 结合的疗效.
- 为了阐明DEC+OLA组合激活的潜在DNA损伤反应 (DDR) 机制.
- 评估这种组合在各种遗传环境中的有效性,包括BRCA1/2状态和同源重组 (HR) 能力.
主要方法:
- 用低剂量的DEC和OLA对dKRAS-PDAC模型的治疗.
- 对抗瘤活性和DNA损伤反应途径 (ATR/ATM) 的评估.
- 评估PARP1-介导修复在治疗疗效中的作用.
- 对具有不同KRAS依赖性,BRCA1/2突变和HR熟练度的瘤的疗效分析.
主要成果:
- DEC和OLA的组合显著增强了dKRAS-PDAC中的抗瘤活性.
- DEC诱导DNA损伤并激活ATR/ATM介导的DDR,其中PARP1介导的修复至关重要.
- OLA与DEC协同作用,提高了疗效,特别是在BRCA1/2-野生型和HR-熟练的瘤中,特别是在dKRAS-PDAC中具有BRCA2突变,抑制转移.
结论:
- 低剂量DEC和OLA的组合通过向DNA损伤和修复途径,在dKRAS-PDAC中显示出强大的抗瘤作用.
- 这种治疗策略甚至在具有熟练同源重组和野生型BRCA1/2.2的瘤中也显示出希望.
- DEC+OLA组合需要进一步的临床研究来治疗胰腺管道腺癌.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K